✦ LIBER ✦

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

✍ Scribed by Ma, W.; Kantarjian, H.; Bekele, B.; Donahue, A. C.; Zhang, X.; Zhang, Z. J.; O'Brien, S.; Estey, E.; Estrov, Z.; Cortes, J.; Keating, M.; Giles, F.; Albitar, M.

Book ID: 119967257
Publisher: American Association for Cancer Research
Year: 2009
Tongue: English
Weight: 226 KB
Volume: 15
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-08-3034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Marrow Fibrosis as a Risk Factor for Pos

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage Dysplasia

✍ Bart L. Scott; Barry E. Storer; Joanne E. Greene; Robert C. Hackman; Frederick R 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Intensive chemotherapy with idarubicin,

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

✍ W. K. Hofmann; G. Heil; C. Zander; S. Wiebe; O. G. Ottmann; L. Bergmann; K. Hoef 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 109 KB

Numerical chromosomal changes and risk o

Numerical chromosomal changes and risk of development of myelodysplastic syndrome–acute myeloid leukemia in patients with Fanconi anemia

✍ Parinda A. Mehta; Richard E. Harris; Stella M. Davies; Mi-Ok Kim; Robin Mueller; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 281 KB

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

Patterns of Infection in Patients With M

Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis

✍ Falantes, Jose F.; Calderón, Cristina; Márquez-Malaver, Francisco J.; Aguilar-Gu 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 291 KB

Cytoreductive treatment with clofarabine

Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome

✍ Stefanie Buchholz; Elke Dammann; Michael Stadler; Juergen Krauter; Gernot Beutel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB